[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
October 9, 1996

Practice Guidelines for Treatment of Peptic Ulcer Disease

Author Affiliations

Abbott Laboratories Abbott Park, Ill

JAMA. 1996;276(14):1135-1136. doi:10.1001/jama.1996.03540140023010

To the Editor.  —The assertion by Dr Soll1 that "single-antibiotic combinations of either clarithromycin or amoxicillin with PPIs... efficacy is less than 70%" is incorrect. While appropriate for amoxicillin, this efficacy level is not valid for clarithromycin. The H pylori eradication rate of 83% for clarithromycin and omeprazole has been published.2 Clarithromycin plus omeprazole yielded consistent eradication rates of 74% or more in 3 of 4 well-controlled studies, which were the basis for FDA approval of this combination.3 These studies were randomized double-blind, multicenter studies with rigorous assessment of H pylori status and follow-up for 6 months posttreatment; they represent both US and European populations. In contrast, essentially all results presented in Figure 1 in the Consensus Statement by Dr Soll were from unblinded studies, mostly conducted in Europe.Differences in study design and assessment of H pylori eradication hamper comparisons among studies. The most effective regimen can only be